StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

APTO has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a report on Wednesday, February 12th. Alliance Global Partners upgraded Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $112.00.

Aptose Biosciences Trading Down 10.3 %

Shares of APTO stock opened at $3.32 on Thursday. The firm has a market capitalization of $7.11 million, a P/E ratio of -1.12 and a beta of 1.14. Aptose Biosciences has a 1 year low of $2.39 and a 1 year high of $51.61. The firm’s fifty day simple moving average is $4.57 and its 200 day simple moving average is $7.54.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 703,384 shares of the biotechnology company’s stock after acquiring an additional 301,634 shares during the quarter. Sigma Planning Corp owned 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.